ASP Isotopes Inc. Common Stock

ASP Isotopes said fiscal 2024 revenue was $4.2 million. Management did not provide EPS, gross margin, or a formal year-over-year revenue comparison on the call. For 2025, the company declined to issue guidance, but said that based on signed contracts and planned output, investors should be able to infer an annualized run rate. Management said Carbon-14 has a take-or-pay contract for a minimum of $2.5 million per year at $24,000 a gram, Ytterbium-176 discussions are around $20,000 a gram with indicated demand of about two kilograms, Silicon-28 has two signed customers and three or four additional prospects, and PET Labs did $4 million last year and should grow nicely this year. Management also said the company should reach cash flow breakeven or better in the second half of 2025 and that no equity raise was expected based on the current balance sheet and cash burn.

Paul Mann framed 2024 and early 2025 as a transition from development to commercial execution, emphasizing that three plants were started up and that the team worked through operational issues as they arose. His tone was confident but cautious: he repeatedly said the company was not giving formal guidance and that timing for permits, orders, and some plant starts remains outside management’s control. He also said the company’s strategy is to expand via multiple isotope plants in South Africa and other regions, likely through a partner model in the U.S. and elsewhere.

No separate CFO remarks were provided in the transcript, but management addressed the financial picture directly. Paul Mann said operating cash flow spend last year was about $58 million, and the company ended the year with about four years of operating free cash flow burden on the balance sheet. He also said the Ytterbium-176 plant likely cost about $3 million, with $2.5 million spent initially and about $0.5 million in capital in the final months, reinforcing the point that these plants are “large and not expensive.” He added that the company expects cash flow breakeven or better in the second half and does not expect to need another equity raise based on current resources.

Analyst questions focused on 2025 revenue potential, cash flow breakeven, timing for new plant construction, Ytterbium-176 commercialization, and the QLE spinout. Mann said the company will not give formal guidance, but pointed investors to signed contracts, estimated annualized run rates, and the expectation that customers want samples before signing Ytterbium supply agreements. On timing, he said the first Ytterbium shipment is likely in the first half, probably by the end of Q2, while the first Nickle-64/Gadolinium-160/Lithium-6 plant could come later this year depending on permits. He also said the QLE spinout could happen soon, but SEC review and government permits remain gating items.